1.75
0.06 (3.55%)
0.06 (3.55%)
Upgrade to Real-Time
Premarket
| Volume | 6,558 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Gamida Cell Ltd | GMDA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.06 | 3.55% | 1.75 | 08:10:21 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.69 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 27 | 6,558 | - | 1.10 - 4.72 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:20:44 | 10 | $ 1.7485 | USD |
Period:
Draw Mode:
Gamida Cell Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 130.52M | 74.58M | 64.64M | $ - | $ - | -1.52 | -1.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 60.50k | 1.20% |
Gamida Cell News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GMDA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.63 | 1.7499 | 1.55 | 1.67 | 415,889 | 0.12 | 7.36% |
| 1 Month | 1.46 | 1.7499 | 1.4101 | 1.59 | 396,370 | 0.29 | 19.86% |
| 3 Months | 1.90 | 1.90 | 1.10 | 1.45 | 530,740 | -0.15 | -7.89% |
| 6 Months | 2.21 | 3.66 | 1.10 | 2.02 | 585,791 | -0.46 | -20.81% |
| 1 Year | 3.24 | 4.72 | 1.10 | 2.35 | 572,829 | -1.49 | -45.99% |
| 3 Years | 4.78 | 15.00 | 1.10 | 4.86 | 528,959 | -3.03 | -63.39% |
| 5 Years | 8.30 | 15.41 | 1.10 | 4.92 | 380,492 | -6.55 | -78.92% |
Gamida Cell Description
| Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients. |